Smith Jason Drew's Form 4 filing
UroGen Pharma Ltd. (URGN) · filed Sep 2, 2022
- Accession no.
- 0001437749-22-021776
- Filed
- Sep 2, 2022
- Trade date
- Aug 31, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $26.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Smith Jason DrewCIK 0001821479 | Officer (General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 31, 2022 | Ordinary Shares | MOption exerciseAcquired | +8,333 | –F1 | – | 15,782 | Direct | |
| Aug 31, 2022 | Ordinary Shares | SSaleDisposed | −3,606 | $7.21 | −$25,999.26 | 12,176 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 31, 2022 | Ordinary Shares | MOption exerciseDisposed | −8,333 | $0.00 | $0 | 8,334 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
Referenced by the price of 1 transaction in Table I.